LOS ANGELES, June 13, 2018 /PRNewswire-PRWeb/ -- MedTech Breakthrough, an independent organization that recognizes
Novoheart's innovations include a fluid-ejecting, three-dimensional 'human heart-in-a-jar', also known as the human ventricular Cardiac Organoid Chamber or hvCOC, which enables the clinically informative assessment of human cardiac pump performance, such as cardiac output, developed pressure, and ejection fraction. The 'human heart-in-a-jar' developed by Novoheart provides an efficient and informative platform for advanced drug discovery. With artificial intelligence integrated into the platform, the human heart-in-a-jar platform can automatically detect drug toxicity and efficacy relevant to the human heart with industry-leading accuracy and proficiency.
"The spirit of the MedTech Breakthrough Awards program is in the recognition of truly innovative healthcare and medical technologies and solutions," said James Johnson, managing director, MedTech Breakthrough. "Novoheart strongly displays that spirit of innovation with its MyHeart™ platform, a powerful solution for drug development that Novheart is pioneering. We are thrilled to recognize Novoheart for its passion and hard work in developing the technology and helping improve the advancement of the drug development process."
The mission of the MedTech Breakthrough Awards is to honor excellence and recognize innovation, diligence, and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data and many more. This year's program attracted more than 3,000 nominations from over 12 different countries across the globe.
"This award is a fantastic validation of our team's dedication to innovation," said Dr. Ronald Li, Co-founder & CEO, Novoheart. "We are very grateful for the industry recognition, and will continue to dedicate our efforts to ensuring that promising new drug candidates will be identified more quickly and accurately, for safe and effective benefit to patients."
About MedTech Breakthrough The MedTech Breakthrough Awards program, part of the Tech Breakthrough Awards organization, is devoted to honoring excellence in medical and health related technology companies, products and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough MedTech companies and products in categories including Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Genomics, Medical Data, Healthcare Cybersecurity and more. For more information visit http://www.MedTechBreakthrough.com.
About Novoheart: Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar', Novoheart's bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.
SOURCE MedTech Breakthrough
Subscribe to our Free Newsletters!